European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai
Eisai | via Reuters European drug regulators on Friday rejected the Alzheimer’s treatment Leqembi from Biogen and Eisai, creating another hurdle for the companies as they scramble to boost uptake of the therapy in the U.S. The European Commission, the European Union’s executive body, has a final say in Leqembi’s […]
